IDEXX Laboratories Inc (IDXX)vsRLX Technology Inc (RLX)
IDXX
IDEXX Laboratories Inc
$575.72
+0.97%
HEALTHCARE · Cap: $45.53B
RLX
RLX Technology Inc
$2.21
+2.31%
CONSUMER DEFENSIVE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 19% more annual revenue ($4.30B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 24.6%. RLX trades at a lower P/E of 21.6x. RLX earns a higher WallStSmart Score of 68/100 (B-).
IDXX
Buy61
out of 100
Grade: C+
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.2%
Fair Value
$462.85
Current Price
$575.72
$112.87 premium
Margin of Safety
+47.9%
Fair Value
$4.68
Current Price
$2.21
$2.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.8%
Reasonable price relative to book value
Revenue surging 46.8% year-over-year
Earnings expanding 81.9% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
ROE of 5.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
IDXX profiles as a mature stock while RLX is a growth play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.70 — expect wider price swings.
RLX is growing revenue faster at 46.8% — sustainability is the question.
RLX generates stronger free cash flow (358M), providing more financial flexibility.
Bottom Line
RLX scores higher overall (68/100 vs 61/100), backed by strong 25.5% margins and 46.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?